$2125 | SAVE $375 | Single User
$4250 | SAVE $750 | Site License
$6375 | SAVE $1,125 | Enterprise License

Chronic Coronary Artery Disease Global Clinical Trials Review, H2, 2015

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2015
[Lowest Price Guaranteed: $2,125]

Published by Global Data: 23 Dec 2015 | 17883 | In Stock
Related Topics: Clinical Trials

Introduction

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2015" provides an overview of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2015

  • Table of Contents

    Table of Contents 2

    List of Tables 3

    List of Figures 4

    Report Guidance 5

    Clinical Trials by Region 6

    Clinical Trials and Average Enrollment by Country 7

    Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

    Top Five Countries Contributing to Clinical Trials in Europe 11

    Top Countries Contributing to Clinical Trials in North America 12

    Top Countries Contributing to Clinical Trials in Middle East and Africa 13

    Top Countries Contributing to Clinical Trials in Central and South America 14

    Clinical Trials by G7 Countries: Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials 15

    Clinical Trials by Phase in G7 Countries 17

    Clinical Trials in G7 Countries by Trial Status 18

    Clinical Trials by E7 Countries: Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials 20

    Clinical Trials by Phase in E7 Countries 22

    Clinical Trials in E7 Countries by Trial Status 23

    Clinical Trials by Phase 24

    In Progress Trials by Phase 25

    Clinical Trials by Trial Status 26

    Clinical Trials by End Point Status 28

    Subjects Recruited Over a Period of Time 29

    Clinical Trials by Sponsor Type 30

    Prominent Sponsors 31

    Top Companies Participating in Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials 33

    Prominent Drugs 35

    Latest Clinical Trials News on Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) 36

    Nov 08, 2015: Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drug 36

    Clinical Trial Profile Snapshots 37

    Appendix 95

    Abbreviations 95

    Definitions 95

    Research Methodology 96

    Secondary Research 96

    About GlobalData 97

    Contact Us 97

    Disclaimer 97

    Source 98

List Of Tables
in Chronic Coronary Artery Disease Global Clinical Trials Review, H2, 2015

List of Tables

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Region, 2015* 6

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14

Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, G7 Countries (%), 2015* 16

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 19

Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, E7 Countries (%), 2015* 21

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 22

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 23

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Phase, 2015* 24

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 25

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 27

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 28

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 29

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 30

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 32

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 34

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 35

List Of Figures, Charts and Diagrams
in Chronic Coronary Artery Disease Global Clinical Trials Review, H2, 2015

List of Figures

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Region (%), 2015* 6

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14

Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, G7 Countries (%), 2015* 15

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18

Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, E7 Countries (%), 2015* 20

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 22

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 23

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 24

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 25

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 26

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 28

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 29

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 30

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 31

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 33

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 35

GlobalData Methodology 96

Additional Details

Publisher

Global Data

Publisher Information

Reference

17883 | GDHC3126CTIDB

Number of Pages

98

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Global Acute and Chronic Myelogenous Leukemia Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Chronic Kidney Disease Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! The Outlook for Wearable Health Tech in Managing Chronic Disease
IntroductionWearable tech – the new golden ticket for patient adherence?Wearable technology is being...
01 May 2016 by FirstWord Pharma USD $591 (normally
USD $695)
More Info
SAVE 15% today! Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016]
IntroductionThis edition presents key opinion leader (KOL) views on recent developments in the chron...
01 Feb 2016 by FirstWord Pharma USD $846 (normally
USD $995)
More Info
SAVE 15% today! Chronic Lymphocytic Leukaemia: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events with the potential to shape the targeted trea...
01 Feb 2016 by FirstWord Pharma USD $846 (normally
USD $995)
More Info
SAVE 15% today! Chronic Lymphocytic Leukaemia: KOL Insight
IntroductionIn the last few years the emergence of new targeted therapies such as AbbVie’s/Janssen’s...
01 Sep 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
IntroductionCombination therapy is set to take centre stage in the treatment of COPD as leading comp...
20 Apr 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Chronic Lymphocytic Leukaemia: KOL Insight
IntroductionChronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until rece...
27 May 2014 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook
IntroductionThe prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, ...
20 Jan 2014 by FirstWord Pharma USD $6,371 (normally
USD $7,495)
More Info
SAVE 15% today! Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
01 Jun 2013 by FirstWord Pharma USD $591 (normally
USD $695)
More Info

This report is published by Global Data

Download Free Report Summary PDF

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2015 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...